Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ACE2
REST API REST API
Homo sapiens
ACE2 is differentially expressed in 181 experiments: 115 organism parts: kidney, lung, ... (113 more);, 115 disease states: normal, adrenocortical carcinoma, ... (113 more);, 46 cell types 198 cell lines 18 compound treatments and 59 other conditions.
Orthologs ACE2_BOVIN (Bos taurus)   Ace2 (Mus musculus)   D3ZLG6_RAT (Rattus norvegicus)   Q3HTU2_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, regulation of cell proliferation, extracellular space, membrane, metallopeptidase activity, peptidase activity, metal ion binding, extracellular region, membrane raft, peptidyl-dipeptidase activity, proteolysis, integral to membrane, carboxypeptidase activity, cell surface, zinc ion binding, viral receptor activity, entry of virus into host cell, angiotensin-mediated drinking behavior, regulation of systemic arterial blood pressure by renin-angiotensin, virion attachment, binding of host cell surface receptor, response to virus, interspecies interaction between organisms, glycoprotein binding, regulation of inflammatory response, regulation of cytokine production, regulation of vasoconstriction, regulation of vasodilation, receptor biosynthetic process, angiotensin catabolic process in blood, positive regulation of reactive oxygen species metabolic process
InterPro Term Peptidase_M2
UniProt Accession C7ECU1, Q9BYF1
Search EB-eye ENSG00000130234
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-11078, E-GEOD-17189, E-GEOD-803, E-AFMX-5, E-GEOD-6573, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-19639, E-GEOD-19397, E-GEOD-2450, E-MTAB-62, E-TABM-420, ... (25 experiments)

Factor Value U/D Experiments
HCC1937
2
E-MTAB-37, E-MTAB-62
T84
2
E-GEOD-1474, E-MTAB-37
JVM3
1
E-MTAB-37
TMK1
1
E-GEOD-15460
GM07019
1
E-TABM-321
MDA-MB231
1
E-GEOD-7307
192 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, ... (27 experiments)

Factor Value U/D Experiments
T cell
1
E-GEOD-13987
adult choroid from 76 y.o. donor
1
E-GEOD-18811
BDCA4+ dentritic cells
1
1
E-AFMX-5
CD56+ NK cells
1
E-AFMX-5
hematopoietic stem cell
1
E-MEXP-872
mesendoderm/endoderm progenitor cell
1
E-MEXP-930
40 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-20602, E-GEOD-9692, E-MTAB-62, ... (35 experiments)

Factor Value U/D Experiments
colon carcinoma
2
E-GEOD-3726, E-MTAB-37
dermatomyositis
1
E-GEOD-5370
uterine fibroid
1
E-MTAB-62
prostate adenocarcinoma
1
E-MTAB-62
Down syndrome
1
E-GEOD-5390
NDV
1
E-GEOD-18791
109 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-MEXP-2218, E-GEOD-6907, E-GEOD-7216, ... (10 experiments)

Factor Value U/D Experiments
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
nickel(II) chloride hexahydrate
1
E-GEOD-6907
CNOT7 + non-targeting
1
1
E-MEXP-2218
ethanol
1
E-GEOD-3113
ponasterone A
1
E-GEOD-3113
Cxcl12
1
E-GEOD-7307
12 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
85
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-22513, E-MEXP-1251, ... (7 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-19665

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023

Genotype
studied in E-MEXP-1437, E-GEOD-17476, E-MEXP-421, E-TABM-321, E-GEOD-17347, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1273

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653

Individual
studied in E-TABM-325, E-MEXP-2069, E-TABM-15, E-GEOD-3606, E-GEOD-16363, ... (28 experiments)

Infection
studied in E-MEXP-561

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-TABM-130, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-1801, E-TABM-84

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-3982

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-7307

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-3494, E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.354 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM